Alentis
Key Facts
| Invested since | 2019 |
| Based in | International |
About the company
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).
Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York.
The portfolio is based on profound knowledge and expertise in liver disease, unique patient-derived model systems and the discovery of a novel, very fundamental mechanism of action underlying these diseases.
Alentis has lead monoclonal antibodies which show consistent compelling efficacy and safety in patient-derived cell and animal models.
Furthermore, Alentis has a proprietary discovery platform enabling fast-track discovery and development of compounds and targets that are relevant in the pathology of late stage liver disease and carcinogenesis.
Do you want to
know more about this company?
Alentis in the news
Zum Artikel
Alentis Therapeutics closes $105 million Series C funding to advance transformational medicines for Claudin-1
Zum Artikel
ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer
More startups from Life Sciences
CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced …
LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI’s patented personalization …
DNTOX GmbH was founded in March 2022 as a spin-off from the IUF – Leibniz Institute for Environmental Medicine Research and is based on the longstanding research work of Professor …
NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support). NovaPump’s catheter-based heart …
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary …
Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill …
Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and …
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – …
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
